U.S., May 24 -- ClinicalTrials.gov registry received information related to the study (NCT06986785) titled 'A Study of BL-B01D1 Combined With Lenvatinib in Patients With Advanced Hepatocellular Carcinoma' on May 15.
Brief Summary: This study is a clinical study to explore the efficacy and safety of BL-B01D1 combined with lenvatinib in patients with advanced hepatocellular carcinoma.
Study Start Date: June, 2025
Study Type: INTERVENTIONAL
Condition:
Advanced Hepatocellular Carcinoma
Intervention:
DRUG: BL-B01D1
Administration by intravenous infusion for a cycle of 3 weeks.
DRUG: Lenvatinib
8mg (body weight =60kg), QD.
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.
Published by HT Digital C...